2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1023

Openness To and Preference For Biologic Therapy Among Patients With Rheumatoid Arthritis Prior To Biologic Initiation: Patient and Prescriber Perspectives
Abstract Number: 785

Ophthalmic Manifestations Of IgG4-Related Disease: A Single-Center Experience
Abstract Number: 2446

Opiate Use In Patients With Ankylosing Spondylitis
Abstract Number: 1126

Opportunistic Computed Tomography Screening For Determining Osteoporosis In Patients With Ankylosing Spondylitis and Spine Fractures
Abstract Number: 1344

Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Abstract Number: 365

Oral Calcium Supplementation Is Associated With Subclinical Atherosclerosis In Rheumatoid Arthritis
Abstract Number: 574

Oral Candidiasis in Systemic Lupus Erythematosus
Abstract Number: 2334

ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
Abstract Number: 2278

Ordering Of Serologic Markers Of Rheumatoid Arthritis Among Primary Care and Subspecialty Providers: Under-Utilization Of Anti-Citrullinated Peptide Antibody Tests By Non-Rheumatologists
Abstract Number: 1793

Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Abstract Number: 455

Oskira-2: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Abstract Number: 456

Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor -á Antagonist
Abstract Number: 2011

Osseous Sarcoidosis: Clinical Presentation, Treatment, and Outcomes. Experience From a Large Tertiary Care Academic Hospital
Abstract Number: 2131

Osteoarthritis Pain: Variability and Clinical Correlations
Abstract Number: 1825

Osteoclast Progenitors, Fibroblast-Like Cells and Draining Lymph Node Cells Induce Catecholaminergic-To-Cholinergic Transition Of Sympathetic Nerve Fibers Under Healthy Conditions But Not In Highly Inflamed Arthritic Tissue

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].